Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
Healthcare
$25.04 +3.46%
+$0.64 today
- Market cap
- $1.70B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
52W Low $8.91High $44.60
Volume 0.27M
Average 0.71M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$172.33M
FY 2025 · Annual
Investing Cash Flow
-$251.89M
FY 2025 · Annual
Financing Cash Flow
$215.28M
FY 2025 · Annual
-47.9% YoYCash Flow Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (119.28M) | (37.12M) | (156.99M) | (377.74M) |
| Depreciation & Amortization | 78K | 113K | 137K | (1.88M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 737K | 3.5M | 10.82M | 26.35M |
| Change in Working Capital | 7.97M | (8.04M) | 25.43M | 951K |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.09M | (418K) | 11.74M | (10.04M) |
| Other Working Capital | 6.88M | (7.62M) | 13.69M | 10.99M |
| Other Non-Cash Items | 44.85M | 11.03M | 925K | 179.98M |
| Operating Cash Flow | (65.65M) | (30.53M) | (119.67M) | (172.33M) |
| Capital Expenditures | (2.2M) | (17K) | (131K) | (18K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (36.42M) | (417.76M) |
| Sales of Investments | 0 | 0 | 6M | 200.89M |
| Other Investing Activities | (2M) | 0 | 0 | (35M) |
| Investing Cash Flow | (2.2M) | (17K) | (30.55M) | (251.89M) |
| Debt Repayment | 0 | 20M | 0 | 0 |
| Common Stock Issued | 59.39M | 116K | 240.64M | 152.95M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (6.06M) | 62.34M |
| Financing Cash Flow | 59.39M | 20.12M | 412.96M | 215.28M |
| Effect of Forex Changes | (41K) | 78K | 157K | (252K) |
| Net Change in Cash | (8.5M) | (10.35M) | 262.89M | (209.19M) |
| Free Cash Flow | (67.85M) | (30.55M) | (119.81M) | (172.35M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$377.7M
+ D&A-$1.9M
+ Stock-Based Comp$26.3M
+ Deferred Tax$0
+ Working Capital$951.0K
+ Other Non-Cash$180.0M
= Operating Cash Flow-$172.3M
- Capex-$18.0K
= Free Cash Flow-$172.4M
Analysis
FY2025 free cash flow is -$172.4M. FCF conversion is 45.6% of net income. Operating cash flow was -$172.3M, with capex of -$18.0K. The largest bridge item is Other Non-Cash at $180.0M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 6, 2026 | |
| 424B5 | 424B5 filing | Nov 6, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 |
Does ZBIO generate free cash flow?
Zenas BioPharma, Inc. (ZBIO) generated -$172.35M of free cash flow in fiscal 2025.
How much operating cash flow does ZBIO produce?
Operating cash flow was -$172.33M, before capital expenditures of $18,000.00.
Continue the stock analysis
Jump to another research area for this company.